Neurelis is a unique company focused on therapies and technologies for disorders involving the central nervous system. Our company is built on a foundation of passion and progress. This passion fuels our drive to successfully deliver innovative products that have the potential to change the lives of patients, caregivers, and healthcare providers.
Neurelis is a neuroscience-based specialty pharmaceutical company dedicated to enhancing therapeutic benefit and addressing unmet needs in patient care.
Our pipeline currently includes VALTOCOTM (diazepam nasal spray), an investigational product candidate being developed as an on-hand rescue treatment to control bouts of increased seizure activity. We also have two product candidates currently in the formulation stage of development. NRL-2 is being developed as a rescue treatment for acute anxiety episodes or panic attacks, and NRL-3 is being developed as a non-invasive acute therapy to stop seizures that have progressed to status epilepticus.
Neurelis has a proprietary technology portfolio that includes Intravail®, ProTek®, and Hydrogel™ for drug delivery enhancement. These three non-invasive drug delivery and stabilization technologies are applicable to a wide range of molecules including therapeutic proteins, peptides, and non-peptide large and small molecules. Our technologies offer exceptional potential value in enhancing drug development and clinical performance.